keyword
https://read.qxmd.com/read/37805954/cubosomal-functionalized-block-copolymer-platform-for-dual-delivery-of-linagliptin-and-empagliflozin-recent-advances-in-synergistic-strategies-for-maximizing-control-of-high-risk-type-ii-diabetes
#41
JOURNAL ARTICLE
Reham Waheed Hammad, Rania Abdel-Basset Sanad, Nevine Shawky Abdelmalak, Randa Latif
A well-made chitosan-PVP block copolymer platform was equipped with highly ordered and uniform nano-channels. This highly adhesive block copolymer platform was designed to ensure the efficient co-delivery of two synergistic-acting hypoglycemic drugs. Linagliptin oral bioavailability is 30% due to poor permeability and intestinal degradation. Its pharmacokinetics shows a non-linear profile. Empagliflozin exhibited decreased permeability and decreased solubility in aqueous media between pH 1 and 7.5. Cubosomes were functionalized as a good microdomain to guest and improve the physicochemical characteristics of drug molecules with decreased permeability and solubility...
October 8, 2023: Drug Delivery and Translational Research
https://read.qxmd.com/read/37716531/a-quantitative-systems-pharmacology-model-of-the-incretin-hormones-gip-and-glp1-glucagon-glucose-insulin-and-the-small-molecule-dpp-4-inhibitor-linagliptin
#42
JOURNAL ARTICLE
Nan Wu, Guohua An
In the current study, we established a comprehensive quantitative systems pharmacology (QSP) model using linagliptin as the model drug, where drug disposition, drug intervention on dipeptidyl peptidase-4 (DPP-4), glucose-dependent insulinotropic peptide (GIP), Glucagon-like peptide-1 (GLP-1), glucagon, glucose, and insulin are integrated together with the cross talk and feedback loops incorporated among the whole glycemic control system. In the final linagliptin QSP model, the complicated disposition of linagliptin was characterized by a 2-compartment pharmacokinetic (PK) model with an enterohepatic cycling (EHC) component as well as target-mediated drug disposition (TMDD) processes occurring in both tissues and plasma, and the inhibitory effect of linagliptin on DPP-4 was determined by the linagliptin-DPP-4 complex in the central compartment based on target occupancy principle...
September 14, 2023: Journal of Pharmaceutical Sciences
https://read.qxmd.com/read/37651251/simplifying-type-2-dm-care-with-linagliptin-a-position-paper
#43
JOURNAL ARTICLE
Ambrish Mithal, Ambady Ramachandran, Arpandev Bhattacharyya, Manoj Chadha, Mala Dharmalingam, Anirban Majumder, Debmalya Sanyal
INTRODUCTION: The burden of type 2 diabetes mellitus (T2DM) is raising dramatically both internationally and in India. It is often observed that multiple therapies or combinations of different drugs are usually required to successfully control hyperglycemia in patients with T2DM. To facilitate effective control of glucose levels, many new agents have been developed over the past few years. MATERIALS AND METHODS: Multiple Advisory Board Meetings were conducted with 87 leading key opinion leaders (KOLs) from diabetes specialty PAN India to understand the simplicity aspect of linagliptin therapy in T2DM patients...
August 2023: Journal of the Association of Physicians of India
https://read.qxmd.com/read/37630980/neuroprotective-impact-of-linagliptin-against-cadmium-induced-cognitive-impairment-and-neuropathological-aberrations-targeting-sirt1-nrf2-axis-apoptosis-and-autophagy
#44
JOURNAL ARTICLE
Hany H Arab, Ahmed H Eid, Shuruq E Alsufyani, Ahmed M Ashour, Azza A K El-Sheikh, Hany W Darwish, Gehan S Georgy
Cadmium is an environmental contaminant associated with marked neurotoxicity and cognitive impairment. Linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, has demonstrated promising neuroprotection against cerebral ischemia and diabetic dementia. However, there has been no study of its effect on cadmium-induced cognitive deficits. In the present work, linagliptin's prospective neuroprotective effects against cadmium-evoked cognitive decline were examined in vivo in rats. The molecular pathways related to oxidative stress, apoptosis, and autophagy were investigated...
July 27, 2023: Pharmaceuticals
https://read.qxmd.com/read/37615707/pylorus-ligation-induced-hyperacidity-synergistic-prophylactic-effects-of-linagliptin-and-l-arginine-via-up-regulation-of-ep4-receptor-subtype-and-improvement-of-vascular-endothelial-damage
#45
JOURNAL ARTICLE
Gihan F Asaad, Dalia O Saleh, Rasha E Mostafa, Azza Hassan, Gehad Abdel Jaleel
Gastric hyperacidity and ulceration are chronic diseases characterized by repeated healing followed by re-exacerbation. The study aims to protect against gastric hyperacidity without interfering with gastric acid secretion. Pylorus ligation-induced hyperacidity is commonly utilized in the induction of gastric ulcers.Forty-two rats were distributed into seven groups (n = 6). Group I comprised sham-operated group. Group II served as pylorus-ligation group. Groups III-VII were given oral Linagliptin (LN; 3 and 6 mg/kg), L-arginine (LA; 150 and 300 mg/kg) and their combination (LN 3 + LA 150 mg/kg), respectively for 7 days...
August 24, 2023: Naunyn-Schmiedeberg's Archives of Pharmacology
https://read.qxmd.com/read/37540652/-indicators-of-diabetes-mellitus-after-liraglutide-sitagliptin-metformin-linagliptin-and-sitagliptin
#46
JOURNAL ARTICLE
Beatriz Atonal-Flores, María de la Luz León-Vázquez, Armando Barranco-Juarez
BACKGROUND: The control of diabetes mellitus is multifactorial, the different therapeutic options make it necessary to compare the effectiveness with previous therapeutic schemes. OBJECTIVE: Analize the indicators of control of diabetes mellitus after incorporating liraglutide, sitagliptin/metformin, linagliptin, and sitagliptin. METHODS: Observational, analytical, longitudinal study. Glucose, glycosylated hemoglobin, and blood pressure were compared after the inclusion of new cues in patients with diabetes mellitus; in addition to the control indicators reported in the unit in october, november, and december 2000, with those of 2021 in the same months...
July 31, 2023: Revista Médica del Instituto Mexicano del Seguro Social
https://read.qxmd.com/read/37532256/evaluation-of-linagliptin-and-insulin-combined-therapy-on-unfolded-protein-response-in-type-1-diabetic-mouse-heart
#47
JOURNAL ARTICLE
Züleyha Doğanyiğit, Aslı Okan, Serpil Taheri, Zeynep Yılmaz, Enes Akyüz, Necdet Demir
The aim of this study is to reveal the effects of the use of linagliptin, a DPP-4 inhibitor due to its beneficial cardiovascular effects, on endoplasmic reticulum stress (ERS) signaling, which is involved in the pathogenesis of cardiovascular complications related to type 1 diabetes. BALB/c female mice (n = 72) were divided into six groups: control, diabetes+insulin, diabetes+linagliptin, diabetes+linagliptin+insulin, diabetes+TUDCA, and diabetes+TUDCA+insulin. Immunohistochemistry and western blot method, qRT-PCR, ELISA method, and malondialdehyde (MDA) measurements were performed...
August 2, 2023: Chemical Biology & Drug Design
https://read.qxmd.com/read/37488616/green-and-white-mekc-for-determination-of-different-anti-diabetic-binary-mixtures-and-their-triple-combo-pill
#48
JOURNAL ARTICLE
Aya R Ahmed, Mohamed A Korany, Shereen M Galal, Marwa A A Ragab
The work introduces green and white sustainable micellar electrokinetic chromatography (MEKC) procedure that could analyze therapeutically related drugs, empagliflozin (EMP), linagliptin (LIN) and metformin (MET) which are antidiabetic drugs with different mechanism of action, in their different pharmaceutical combinations. The method not only comply with the green analytical concepts, but also it is in line with sustainable analytical concepts as it is economic by applying the same operating conditions to analyze different pharmaceuticals in quality control (QC) labs which is a crucial step in QC labs and research centers to save time, effort, and money...
July 25, 2023: BMC chemistry
https://read.qxmd.com/read/37467664/a-deep-learning-based-drug-repurposing-screening-and-validation-for-anti-sars-cov-2-compounds-by-targeting-the-cell-entry-mechanism
#49
JOURNAL ARTICLE
Yingjia Yao, Yunhan Zhang, Zexu Li, Zhisong Chen, Xiaofeng Wang, Zihan Li, Li Yu, Xiaolong Cheng, Wei Li, Wen-Jie Jiang, Hua-Jun Wu, Zezhong Feng, Jinfu Sun, Teng Fei
The recent outbreak of Corona Virus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been a severe threat to the global public health and economy, however, effective drugs to treat COVID-19 are still lacking. Here, we employ a deep learning-based drug repositioning strategy to systematically screen potential anti-SARS-CoV-2 drug candidates that target the cell entry mechanism of SARS-CoV-2 virus from 2635 FDA-approved drugs and 1062 active ingredients from Traditional Chinese Medicine herbs...
July 12, 2023: Biochemical and Biophysical Research Communications
https://read.qxmd.com/read/37449424/baseline-cardiovascular-risk-factor-control-in-patients-with-type-2-diabetes-and-coronary-disease-versus-stroke-secondary-analysis-of-cardiovascular-outcome-trials
#50
JOURNAL ARTICLE
Priyadarshini Balasubramanian, Walter N Kernan, Kevin N Sheth, Anne Pernille Ofstad, Julio Rosenstock, Christoph Wanner, Bernard Zinman, Michaela Mattheus, Nikolaus Marx, Silvio E Inzucchi
BACKGROUND: Patients with type 2 diabetes (T2D) and cardiovascular disease are at increased risk for recurrent ischemic events. Cardiovascular risk factor control is vital for secondary prevention, but how this compares among individuals with different T2D macrovascular complications is unknown. We aimed to determine if there might be differences in risk factor control in patients with T2D with previous stroke versus coronary artery disease (CAD). METHODS: Cross-sectional analyses were performed on 12 856 patients with T2D with prior history of stroke with or without CAD from 3 diabetes cardiovascular outcome trials: CARMELINA (The Cardiovascular and Renal Microvascular Outcome Study With Linagliptin), EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients), and CAROLINA (The Cardiovascular Outcome Study of Linagliptin vs Glimepiride in Type 2 Diabetes)...
August 2023: Stroke; a Journal of Cerebral Circulation
https://read.qxmd.com/read/37421842/exploring-the-molecular-mechanism-of-linagliptin-in-osteosarcoma-cell-lines-for-anti-cancer-activity
#51
JOURNAL ARTICLE
Asiye Gok Yurttas, Mustafa Fatih Dasci
BACKGROUND: Finding new applications for widely used current drugs is a fast and effective technique for discovering new anticancer chemicals. Osteosarcoma (OS), the most prevalent form of bone cancer, has several side effects that significantly lower patients' quality of life. This study aims to systematically examine the anti-cancer activity of linagliptin (LG) in the osteosarcoma cell line Saos-2. METHODS: MTT assays and flow cytometry were used to assess cell viability and apoptosis, respectively...
June 22, 2023: Pathology, Research and Practice
https://read.qxmd.com/read/37417375/overall-and-inter-individual-effect-of-four-different-drug-classes-on-soluble-urokinase-plasminogen-activator-receptor-in-type-1-and-type-2-diabetes
#52
JOURNAL ARTICLE
Viktor Rotbain Curovic, Morten B Houlind, Marjolein Y A M Kroonen, Niels Jongs, Emilie H Zobel, Tine W Hansen, Juliette Tavenier, Jesper Eugen-Olsen, Gozewijn D Laverman, Adriaan Kooy, Frederik Persson, Peter Rossing, Hiddo J L Heerspink
AIM: To evaluate the effect of four different drug classes on soluble urokinase plasminogen activator receptor (suPAR), a biomarker active in multiple inflammatory processes and a risk factor for complications, in people with type 1 and type 2 diabetes. METHODS: We conducted post hoc analyses of a randomized, open-label, crossover trial including 26 adults with type 1 and 40 with type 2 diabetes with urinary albumin-creatinine ratio ≥30 and ≤500 mg/g assigned to 4-week treatments with telmisartan 80 mg, empagliflozin 10 mg, linagliptin 5 mg and baricitinib 2 mg, separated by 4-week washouts...
July 7, 2023: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/37405760/dpp-4-inhibitors-attenuate-fibrosis-after-glaucoma-filtering-surgery-by-suppressing-the-tgf-%C3%AE-smad-signaling-pathway
#53
JOURNAL ARTICLE
Masaaki Yoshida, Taiki Kokubun, Kota Sato, Satoru Tsuda, Yu Yokoyama, Noriko Himori, Toru Nakazawa
PURPOSE: This study investigated the effect of dipeptidyl peptidase-4 inhibitors (DPP-4is) on fibrosis after glaucoma filtering surgery with clinical data and an in vitro model that used transforming growth factor-β (TGF-β) to induce human Tenon's fibroblast (HTF) fibrosis. METHODS: The medical records of 41 eyes of 35 patients with diabetes with neovascular glaucoma (NVG) who received initial trabeculectomy were retrospectively reviewed. The surgical success rate was compared between cases that received (n = 23) and did not receive (n = 18) DPP-4i treatment for diabetes...
July 3, 2023: Investigative Ophthalmology & Visual Science
https://read.qxmd.com/read/37385308/targeting-dpp4-rbd-interactions-by-sitagliptin-and-linagliptin-delivers-a-potential-host-directed-therapy-against-pan-sars-cov-2-infections
#54
JOURNAL ARTICLE
Shailendra Mani, Anupamjeet Kaur, Kamini Jakhar, Geetika Kumari, Sudipta Sonar, Amit Kumar, Sudesna Das, Santosh Kumar, Vijay Kumar, Rakesh Kundu, Anil Kumar Pandey, Umesh Prasad Singh, Tanmay Majumdar
Highly mutated SARS-CoV-2 is known aetiological factor for COVID-19. Here, we have demonstrated that the receptor binding domain (RBD) of the spike protein can interact with human dipeptidyl peptidase 4 (DPP4) to facilitate virus entry, in addition to the usual route of ACE2-RBD binding. Significant number of residues of RBD makes hydrogen bonds and hydrophobic interactions with α/β-hydrolase domain of DPP4. With this observation, we created a strategy to combat COVID-19 by circumventing the catalytic activity of DPP4 using its inhibitors...
June 27, 2023: International Journal of Biological Macromolecules
https://read.qxmd.com/read/37363571/mitochondrial-encephalomyopathy-lactic-acidosis-and-stroke-like-episodes-syndrome-a-case-report-from-nepal
#55
JOURNAL ARTICLE
Ram C Subedi, Raju Paudel, Sharma Paudel, Lekhjung Thapa, Subash Phuyal, Naresh Kharbuja, Ayush Adhikari
UNLABELLED: Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like syndrome (MELAS) is a rare neurodegenerative inherited disorder that is characterized by stroke-like episodes, seizures, endocrine, and multiple system involvement. It is important to consider it as a differential diagnosis in a young patient with stroke-like episodes as it is progressive and has multiple complications. CASE PRESENTATION: A 28-year-old male presented with slurring of speech and drowsiness for 7 h...
June 2023: Annals of Medicine and Surgery
https://read.qxmd.com/read/37326010/pharmacologic-heterogeneity-and-risk-of-severe-hypoglycemia-with-concomitant-use-of-sulfonylureas-and-dpp-4-inhibitors-population-based-cohort-study
#56
JOURNAL ARTICLE
Jenny Dimakos, Ying Cui, Robert W Platt, Christel Renoux, Kristian B Filion, Antonios Douros
Dipeptidyl peptidase-4 inhibitors (DPP-4i) interact with sulfonylureas to increase their risk of hypoglycemia. Our population-based study assessed whether intraclass pharmacologic heterogeneity among sulfonylureas (long- vs. short-acting) and DPP-4i (peptidomimetic vs. non-peptidomimetic) modifies this interaction. We conducted a cohort study using the UK's Clinical Practice Research Datalink Aurum linked to hospitalization and vital statistics data. We assembled a cohort of patients initiating sulfonylureas (2007-2020)...
September 2023: Clinical Pharmacology and Therapeutics
https://read.qxmd.com/read/37287831/high-fat-diet-and-palmitic-acid-amplify-airway-type-2-inflammation
#57
JOURNAL ARTICLE
Kris Genelyn Dimasuay, Bruce Berg, Niccolette Schaunaman, Fernando Holguin, Daniel Winnica, Hong Wei Chu
INTRODUCTION: Metabolic dysfunction such as elevated levels of saturated fatty acids (SFA) may play a role in obese asthma, but its contribution to airway inflammation remains unclear. We sought to determine the role of high-fat diet (HFD) and palmitic acid (PA), a major form of SFA, in regulating type 2 inflammation. METHODS: Airway samples from asthma patients with or without obesity, mouse models and human airway epithelial cell culture were utilized to test if SFA amplify type 2 inflammation...
2023: Front Allergy
https://read.qxmd.com/read/37233949/soluble-dipeptidyl-peptidase-4-induces-epithelial-mesenchymal-transition-through-tumor-growth-factor-%C3%AE-receptor
#58
JOURNAL ARTICLE
Cheng-Wei Huang, Shih-Yi Lee, Chen-Xuan Du, Hui-Chun Ku
BACKGROUND: Kidney fibrosis is the final manifestation of chronic kidney disease, a condition mainly caused by diabetic nephropathy. Persistent tissue damage leads to chronic inflammation and excessive deposition of extracellular matrix (ECM) proteins. Epithelial-mesenchymal transition (EMT) is involved in a variety of tissue fibrosis and is a process during which epithelial cells transform into mesenchymal-like cells and lose their epithelial functionality and characteristics Dipeptidyl peptidase-4 (DPP4) is widely expressed in tissues, especially those of the kidney and small intestine...
May 26, 2023: Pharmacological Reports: PR
https://read.qxmd.com/read/37222255/the-combination-of-linagliptin-and-metformin-rescues-bone-loss-in-type-2-diabetic-osteoporosis
#59
JOURNAL ARTICLE
Jing Liu, Zhihong Liu, Ming Lu, Yanrong Zhang
To develop an approach to reduce the type 2 diabetic osteoporosis, this study investigated the protective effects of the combination of linagliptin and metformin against osteoporosis. Micro-CT and dynamic biomechanical measurements were used to determine the bone microstructure in the type 2 diabetes mellitus (T2DM) rats. MC3T3-E1 cells were cultured in high glucose environments. In addition, we used qRT-PCR and Western blotting to assess osteogenic markers and p38 and extracellular signal-regulated kinase (ERK) protein expression...
May 25, 2023: Journal of Drug Targeting
https://read.qxmd.com/read/37163899/facile-decoration-of-one-pot-fluorescence-probe-patterned-reaction-for-sensing-and-ultrasensitive-determination-of-tradjenta-a-new-type-2-diabetes-oral-therapy
#60
JOURNAL ARTICLE
Ahmed Abdulhafez Hamad, Bassam S Mohammed, Yasser F Hassan, Afnan S Batubara, Ahmed M Haredy
Type 2 diabetes can be cured by using tradjenta (also known as Linagliptin), a new therapeutic drug that is an inhibitor of the dipeptidyl peptidase-4 enzyme. Tradjenta is administered orally alone or in combination with metiguanide or empagliflozin. An easy and specific fluorimetric analysis of Tradjenta was developed and demonstrated in the present investigation. The Hantzsch reaction method, which generates a fluorescent dihydropyridine derivative, is the basis of this assay. In a Toerell-Stenhagen buffered solution, the unsubstituted amine group of Tradjenta interacted with 2,4-Pentadione/Oxomethane...
April 30, 2023: Spectrochimica Acta. Part A, Molecular and Biomolecular Spectroscopy
keyword
keyword
19869
3
4
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.